What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials
Crossref DOI link: https://doi.org/10.1007/s40119-020-00163-w
Published Online: 2020-02-05
Published Print: 2020-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Furtado, Remo H. M.
Giugliano, Robert P.
Article History
Received: 5 December 2019
First Online: 5 February 2020